
Home | Insulet
Insulet (NASDAQ: PODD), headquartered in Acton, Massachusetts, and with offices and manufacturing facilities around the world, is a global company with growing reach. We strive to bring our innovations to all who need them, wherever they are.
About Insulet
Insulet (NASDAQ: PODD) is an innovative medical device company improving the lives of people with diabetes and other conditions through its Omnipod delivery system.
Insulet Corporation - Insulet Reports Full Year 2024 Revenue ...
3 days ago · Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months and full year ended …
Insulet Corporation - Investor Relations
Dec 4, 2024 · Insulet Corporation is an innovative medical device company based in Acton, Massachusetts. It was founded in 2000 with the mission of improving the lives of people with diabetes. Specifically, through our revolutionary Omnipod Insulin Management System, we seek to expand the use of insulin pump therapy.
Insulet Reports Full Year 2024 Revenue Increase of 22% and ...
3 days ago · Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its ...
About Insulet | Insulin Pump Therapy - Omnipod
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
Insulet Corporation (PODD) Stock Price, News, Quote & History ...
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.